/MTEM

MTEM Stock - Molecular Templates, Inc.

Q: What is the analyst price target for MTEM?

Analyst price target information is not currently available for MTEM.

Q: What is MTEM's market cap?

Market capitalization information is not currently available for MTEM.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Jun 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MTEM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.53

52W High$1.59

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$57.31M	$19.75M	$38.70M	$18.84M	$22.27M
Gross Profit	$50.40M	$11.95M	$32.00M	$-74,120,000	$-28,249,000
Gross Margin	87.9%	60.5%	82.7%	-393.3%	-126.8%
Operating Income	$-10,466,000	$-88,871,000	$-80,074,000	$-100,842,000	$-70,449,000
Net Income	$-8,124,000	$-92,718,000	$-83,009,000	$-104,916,000	$-69,421,000
Net Margin	-14.2%	-469.4%	-214.5%	-556.7%	-311.7%
EPS	$-1.80	$-24.75	$-22.50	$-33.06	$-27.62

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Visit Website

Earnings History & Surprises

MTEM

Beat Rate

56%

Last 16 quarters

Avg Surprise

-11.7%

EPS vs Estimate

Beats / Misses

9/6

1 met exactly

Latest EPS

$-1.23

Q3 2024

EPS Surprise History

Q4 22

+8.3%

$-6.60vs$-7.20

Q1 23

+40.0%

$-0.18vs$-0.30

Q1 23

-56.0%

$-5.85vs$-3.75

Q3 23

+37.1%

$-3.30vs$-5.25

Q4 23

+69.6%

$-0.82vs$-2.70

Q1 24

+65.2%

$-0.73vs$-2.10

Q2 24

+110.3%

$0.08vs$-0.78

Q3 24

+14.6%

$-1.23vs$-1.44

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	Jun 4, 2025	—	—	—	—
Q2 2025	May 29, 2025	—	—	—	—
Q1 2025	Mar 28, 2025	—	—	—	—
Q4 2024	Dec 27, 2024	$-1.03	—	—	—
Q3 2024	Aug 14, 2024	$-1.44	$-1.23	+14.6%	✓ BEAT
Q2 2024	May 15, 2024	$-0.78	$0.08	+110.3%	✓ BEAT
Q1 2024	Mar 29, 2024	$-2.10	$-0.73	+65.2%	✓ BEAT
Q4 2023	Nov 13, 2023	$-2.70	$-0.82	+69.6%	✓ BEAT
Q3 2023	Aug 10, 2023	$-5.25	$-3.30	+37.1%	✓ BEAT
Q1 2023	Mar 30, 2023	$-3.75	$-5.85	-56.0%	✗ MISS
Q1 2023	Mar 27, 2023	$-0.30	$-0.18	+40.0%	✓ BEAT
Q4 2022	Nov 10, 2022	$-7.20	$-6.60	+8.3%	✓ BEAT
Q3 2022	Aug 11, 2022	$-6.45	$-6.60	-2.3%	✗ MISS
Q2 2022	May 12, 2022	$-6.30	$-5.70	+9.5%	✓ BEAT
Q1 2022	Mar 28, 2022	$-2.70	$-2.70	0.0%	= MET
Q4 2021	Nov 15, 2021	$-4.80	$-8.10	-68.8%	✗ MISS
Q3 2021	Aug 12, 2021	$-1.95	$-4.20	-115.4%	✗ MISS
Q2 2021	May 13, 2021	$4.20	$-7.65	-282.1%	✗ MISS
Q1 2021	Mar 18, 2021	$-6.45	$-7.95	-23.3%	✗ MISS
Q4 2020	Nov 5, 2020	$-7.50	$-7.05	+6.0%	✓ BEAT

Frequently Asked Questions about MTEM

What is MTEM's current stock price?

Molecular Templates, Inc. (MTEM) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for MTEM?

No analyst price targets are currently available for this stock.

What sector is Molecular Templates, Inc. in?

Molecular Templates, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is MTEM's market cap?

Molecular Templates, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does MTEM pay dividends?

No, Molecular Templates, Inc. does not currently pay a dividend to shareholders.